Study guide

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines

Key Takeaways Explain This Topic AI

The American Society of Anesthesiologists (ASA) Physical Status classification grades systemic illness severity from ASA I (healthy) to ASA VI (brain-dead organ donor) with an emergency suffix 'E'; while correlating with perioperative morbidity and mortality, it has moderate inter-rater reliability and does not measure surgical procedural risk.

The Revised Cardiac Risk Index (RCRI / Lee Index) predicts Major Adverse Cardiac Events (MACE) using 6 independent predictors: high-risk surgery, ischemic heart disease, heart failure history, cerebrovascular disease, insulin-treated diabetes, and preoperative serum creatinine > 170 μ mol/L >170\text{ }\mu\text{mol/L} > 170 μ mol/L ( > 2.0 mg/dL >2.0\text{ mg/dL} > 2.0 mg/dL ); a score ≥ 3 \ge 3 ≥ 3 indicates high cardiac risk ( ≥ 11 % \ge 11\% ≥ 11% ).

Functional capacity measured in Metabolic Equivalents of Task ( 1 MET = 3.5 mL O 2 / kg/min 1\text{ MET} = 3.5\text{ mL } \text{O}_2/\text{kg/min} 1 MET = 3.5 mL O 2 ​ / kg/min ) is a critical determinant of cardiopulmonary reserve; patients unable to achieve 4 METs 4\text{ METs} 4 METs (e.g., climbing a flight of stairs or walking up a hill) have significantly elevated perioperative cardiopulmonary complication rates.

European adult fasting guidance (ESA 2011) allows clear fluids, including carbohydrate drinks, until 2 hours 2\text{ hours} 2 hours and solids until 6 hours 6\text{ hours} 6 hours before elective surgery; the ESAIC 2022 paediatric guideline allows clear fluids until 1 hour 1\text{ hour} 1 hour , breast milk 3 hours 3\text{ hours} 3 hours and formula or non-human milk 4 hours 4\text{ hours} 4 hours .

Gastric point-of-care ultrasound (POCUS) assesses aspiration risk: Perlas Grade 0 represents an empty antrum in both supine and right lateral decubitus (RLD) positions; Grade 1 indicates clear fluid visible only in RLD ( < 1.5 mL/kg <1.5\text{ mL/kg} < 1.5 mL/kg ); Grade 2 shows fluid in both positions ( > 1.5 mL/kg >1.5\text{ mL/kg} > 1.5 mL/kg ), indicating a high-risk full stomach.

Last updated: October 2026

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines

Preoperative evaluation is the clinical foundation of anaesthetic practice. It transitions anaesthesia from an acute intraoperative intervention into a comprehensive perioperative discipline designed to identify occult pathophysiology, quantify organ-specific reserve, optimize chronic medical conditions, formulate tailored anaesthetic plans, and obtain informed patient consent.

1. Goals and Structure of Preoperative Evaluation

The fundamental goals of the preoperative consultation include:

Baseline Physiological Appraisal: Establishing baseline cardiopulmonary, renal, metabolic, and neurological status.

Identification of Undiagnosed Pathology: Detecting unsuspected aortic stenosis, severe pulmonary hypertension, obstructive sleep apnoea, or difficult airway anatomy.

Risk Stratification and Shared Decision-Making: Formulating objective quantitative risk estimates for major adverse cardiovascular, pulmonary, and mortality outcomes to guide informed consent.

Comorbidity Optimization: Initiating disease-modifying interventions (e.g., intravenous iron for anemia, smoking cessation, optimization of heart failure pharmacotherapy).

Formulating an Anaesthetic Strategy: Planning airway management techniques, invasive monitoring lines, regional anaesthetic blocks, and postoperative care disposition (day surgery, post-anaesthesia care unit, or high-dependency/intensive care unit).

2. ASA Physical Status Classification System

Introduced in 1941 and revised in 2014 and 2020 by the American Society of Anesthesiologists, the ASA Physical Status (ASA-PS) classification system remains the most universally utilized clinical scale for grading a patient's overall physical condition. [ ASA PHYSICAL STATUS CLASSIFICATION ]

  • |
  • +-----------------------------+-----------------------------+
  • | | |
  • [ ASA I - III ] [ ASA IV - V ] [ ASA VI ]
  • (Low to Severe Disease) (Life-Threatening / Moribund) (Brain-Dead Organ Donor)
  • | | |
  • ASA I: Normal healthy ASA IV: Constant threat Declared brain-dead;
  • ASA II: Mild systemic ASA V: Moribund without op organ procurement
  • ASA III: Substantive limit
  • * Append 'E' to ANY class for EMERGENCY surgery *
  • ASA Physical Status Categories

ASA I: A normal healthy patient. Non-smoker, minimal or no alcohol consumption, excellent functional capacity.

ASA II: A patient with mild systemic disease without substantive functional limitations. Examples: well-controlled hypertension, well-controlled type 2 diabetes mellitus, mild asthma, active cigarette smoker, social drinker, pregnancy, obesity ( 30 < BMI < 40 kg/m 2 30 < \text{BMI} < 40\text{ kg/m}^2 30 < BMI < 40 kg/m 2 ).

ASA III: A patient with severe systemic disease that results in substantive functional limitations; one or more moderate-to-severe diseases. Examples: poorly controlled diabetes or hypertension, stable angina, history of myocardial infarction ( > 3 months >3\text{ months} > 3 months prior), chronic obstructive pulmonary disease (COPD), end-stage renal disease (ESRD) on scheduled hemodialysis, morbid obesity ( BMI ≥ 40 kg/m 2 \text{BMI} \ge 40\text{ kg/m}^2 BMI ≥ 40 kg/m 2 ), implanted pacemaker, moderate reduction of ejection fraction.

ASA IV: A patient with severe systemic disease that is a constant threat to life. Examples: recent myocardial infarction or stroke ( < 3 months <3\text{ months} < 3 months prior), unstable angina, ongoing cardiac ischemia, severe symptomatic valvular stenosis, severe reduction of ejection fraction, sepsis, acute renal failure, symptomatic heart failure.

ASA V: A moribund patient who is not expected to survive without the operation. Examples: ruptured abdominal or thoracic aortic aneurysm, massive polytrauma with hemorrhagic shock, intracranial bleed with midline shift and mass effect, ischemic bowel with multiorgan failure.

ASA VI: A declared brain-dead patient whose organs are being removed for donor purposes.

Emergency Modifier ('E'): Appended to any class (e.g., ASA IIE, ASA IVE) when a delay in surgical treatment would significantly increase the threat to the patient's life or body part.

  • ASA Class Clinical Definition Key Clinical Examples
  • ASA I Normal, healthy patient Healthy non-smoker, elective hernia repair

ASA II Mild systemic disease, no functional limitation Controlled hypertension, smoker, BMI 32 kg/m 2 32\text{ kg/m}^2 32 kg/m 2

ASA III Severe systemic disease, substantive functional limitation Stable CAD, COPD, ESRD on dialysis, BMI 42 kg/m 2 42\text{ kg/m}^2 42 kg/m 2

ASA IV Severe disease, constant threat to life Recent MI ( < 3 <3 < 3 months), severe aortic stenosis, severe CHF

ASA V Moribund, survival unlikely without operation Ruptured aortic aneurysm, severe shock, intracranial herniation

ASA VI Brain-dead organ donor Organ procurement surgery

Mortality rises steeply with ASA class, but the ASA does not publish class-specific mortality figures; reported rates vary widely with the population and the operation.

Clinical Utility and Inherent Limitations

While ASA-PS exhibits a robust, statistically significant correlation with perioperative morbidity, intensive care admission, and 30-day mortality, it possesses two major limitations:

Moderate Inter-Rater Reliability: Multiple clinical audits demonstrate that anaesthetists frequently assign different ASA scores to the same patient (e.g., classifying a compensated diabetic smoker as ASA II versus ASA III).

Absence of Procedural Risk: The ASA-PS evaluates solely the patient's physiological state, ignoring surgical magnitude. An ASA I patient undergoing a complex Whipple pancreatoduodenectomy faces dramatically higher procedural morbidity than an ASA III patient undergoing cataract extraction under topical anaesthesia.

3. Cardiovascular Risk Stratification: RCRI, METs, and ESC/ESAIC Guidelines

Cardiovascular complications—including acute myocardial infarction, acute pulmonary edema, ventricular fibrillation, and cardiac arrest—represent the primary causes of perioperative death in non-cardiac surgery.

The Revised Cardiac Risk Index (RCRI / Lee Index)

Developed by Lee and colleagues, the RCRI is the most widely validated and utilized risk-scoring tool for predicting Major Adverse Cardiac Events (MACE: myocardial infarction, pulmonary edema, ventricular fibrillation, complete heart block, or cardiac arrest) within 30 days of non-cardiac surgery.

The RCRI assesses 6 independent clinical predictors , each scoring 1 point:

High-Risk Surgery: Intraperitoneal, intrathoracic, or suprainguinal vascular surgery.

History of Ischemic Heart Disease: Prior myocardial infarction, positive exercise stress test, current complaint of angina pectoris, use of sublingual nitrate therapy, or ECG showing pathological Q waves.

History of Congestive Heart Failure: Prior clinical diagnosis of heart failure, history of paroxysmal nocturnal dyspnea, history of pulmonary edema, physical findings of bilateral rales, an S 3 S_3 S 3 ​ gallop, or chest radiograph demonstrating pulmonary venous congestion.

History of Cerebrovascular Disease: Prior transient ischemic attack (TIA) or stroke.

Preoperative Treatment with Insulin: Diabetes mellitus managed with insulin therapy (diet- or oral-hypoglycemic-controlled diabetes does not score a point).

Preoperative Renal Impairment: Preoperative serum creatinine > 170 μ mol/L >170\text{ }\mu\text{mol/L} > 170 μ mol/L ( > 2.0 mg/dL >2.0\text{ mg/dL} > 2.0 mg/dL ).

RCRI Score Risk Class Estimated 30-Day MACE Rate (Original Cohort) Estimated 30-Day MACE Rate (Contemporary Cohorts)

  • 0 Predictors Class I (Very Low) 0.4 % 0.4\% 0.4% 3.9 % 3.9\% 3.9%
  • 1 Predictor Class II (Low) 0.9 % 0.9\% 0.9% 6.0 % 6.0\% 6.0%
  • 2 Predictors Class III (Moderate) 6.6 % 6.6\% 6.6% 10.1 % 10.1\% 10.1%
  • ≥ 3 \ge 3 ≥ 3 Predictors Class IV (High) 11.0 % 11.0\% 11.0% 15.0 – 20.0 % 15.0\text{--}20.0\% 15.0 – 20.0%

Note on Modern Rates: Contemporary cohorts report higher baseline MACE rates than Lee's 1999 study due to high-sensitivity cardiac troponin assays detecting subclinical myocardial injury after noncardiac surgery (MINS).

Functional Capacity Assessment (METs)

Functional capacity is a powerful independent predictor of perioperative cardiovascular and pulmonary outcomes. It is quantified in Metabolic Equivalents of Task (METs) , where: 1 MET = 3.5 mL O 2 / kg/min 1\text{ MET} = 3.5\text{ mL } \text{O}_2/\text{kg/min} 1 MET = 3.5 mL O 2 ​ / kg/min This represents the resting basal oxygen consumption of an average seated adult.

Poor Functional Capacity ( < 4 METs <4\text{ METs} < 4 METs ): Inability to climb two flights of stairs, walk up a steep hill, or walk at 4 km/h 4\text{ km/h} 4 km/h on level ground. Associated with significantly higher postoperative cardiac events, pulmonary morbidity, and 30-day mortality.

Moderate Functional Capacity ( 4 – 10 METs 4\text{--}10\text{ METs} 4 – 10 METs ): Able to climb a flight of stairs without stopping, perform heavy housework (scrubbing floors, moving furniture), or walk on level ground at 6 km/h 6\text{ km/h} 6 km/h .

Excellent Functional Capacity ( > 10 METs >10\text{ METs} > 10 METs ): Participation in strenuous sports (swimming, singles tennis, running, cycling) or heavy manual labor. Patients with > 10 METs >10\text{ METs} > 10 METs rarely experience perioperative cardiac complications even in the presence of stable coronary artery disease. [ FUNCTIONAL CAPACITY IN METs ]

  • |
  • +-------------------------------+-------------------------------+
  • | | |
  • [ < 4 METs ] [ 4 - 10 METs ] [ > 10 METs ]
  • (Poor Reserve) (Moderate Reserve) (Excellent Reserve)
  • | | |
  • Cannot climb 1-2 flights • Climbs 1-2 flights of stairs • Strenuous athletics
  • Cannot walk up a hill • Walks briskly on level ground • Running, swimming
  • High perioperative risk • Heavy housework / scrubbing • Negligible cardiac risk
  • ESC/ESAIC Perioperative Cardiovascular Guidelines

The 2022 European Society of Cardiology (ESC) guideline on non-cardiac surgery, endorsed by ESAIC, recommends a structured clinical pathway:

High-Sensitivity Cardiac Troponin (hs-cTnI / hs-cTnT): Recommended preoperatively and at 24 and 48 hours postoperatively in patients undergoing intermediate- or high-risk non-cardiac surgery who have known cardiovascular disease, cardiovascular risk factors (including age ≥ 65 years \ge 65\text{ years} ≥ 65 years ), or symptoms suggestive of cardiovascular disease (Class I).

B-Type Natriuretic Peptides (BNP / NT-proBNP): Measurement should be considered (Class IIa) in the same high-risk population before intermediate- or high-risk surgery; the Canadian guideline uses age ≥ 65 \ge 65 ≥ 65 or RCRI ≥ 1 \ge 1 ≥ 1 as its trigger. Elevated preoperative NT-proBNP independently predicts 30-day mortality and MACE.

12-Lead Electrocardiogram (ECG): Recommended in patients with known cardiovascular disease, symptoms, or undergoing intermediate- to high-risk surgery. Not routinely recommended in asymptomatic patients undergoing low-risk surgery.

Transthoracic Echocardiography (TTE): Indicated in patients with newly detected murmurs, unexplained dyspnea, suspected or known heart failure with clinical deterioration, or prior to high-risk surgery in patients with poor or unknown functional capacity. Routine TTE is not recommended in stable, asymptomatic individuals.

Non-Invasive Stress Imaging: Pharmacological (dobutamine or dipyridamole) stress echocardiography or myocardial perfusion scintigraphy is indicated only in patients with poor functional capacity ( < 4 METs <4\text{ METs} < 4 METs ) scheduled for high-risk non-cardiac surgery if the results would alter clinical management (e.g., prompting coronary revascularization prior to elective surgery).

4. Pulmonary Risk Assessment: The ARISCAT Score

Postoperative Pulmonary Complications (PPCs)—including atelectasis, pneumonia, acute respiratory failure, and acute respiratory distress syndrome (ARDS)—occur with equal or greater frequency than cardiac complications and markedly prolong hospital length of stay.

The ARISCAT Score (Assess Respiratory Risk in Surgical Patients in Catalonia) evaluates 7 independent clinical risk factors for PPCs:

  • ARISCAT Predictor Variable Clinical Category Assigned Points
  • Age (years) ≤ 50 \le 50 ≤ 50 0
  • 51 – 80 51\text{--}80 51 – 80 3
  • > 80 > 80 > 80 16
  • Preoperative S p O 2 Sp\text{O}_2 Sp O 2 ​ on room air ≥ 96 % \ge 96\% ≥ 96% 0
  • 91 – 95 % 91\text{--}95\% 91 – 95% 8
  • ≤ 90 % \le 90\% ≤ 90% 24
  • Respiratory infection in prior month Absent / Present 0 / 17
  • Preoperative Anemia ( H b ≤ 100 g/L Hb \le 100\text{ g/L} H b ≤ 100 g/L ) Absent / Present 0 / 11
  • Surgical Incision Site Peripheral 0
  • Upper abdominal 15
  • Intrathoracic 24
  • Duration of Surgery < 2 hours < 2\text{ hours} < 2 hours 0
  • 2 – 3 hours 2\text{--}3\text{ hours} 2 – 3 hours 16
  • > 3 hours > 3\text{ hours} > 3 hours 23
  • Emergency Surgery Elective / Emergency 0 / 8
  • ARISCAT Risk Stratification

Low Risk ( < 26 points <26\text{ points} < 26 points ): PPC risk ≈ 1.6 % \approx 1.6\% ≈ 1.6% .

Intermediate Risk ( 26 – 44 points 26\text{--}44\text{ points} 26 – 44 points ): PPC risk ≈ 13.3 % \approx 13.3\% ≈ 13.3% .

High Risk ( ≥ 45 points \ge 45\text{ points} ≥ 45 points ): PPC risk ≈ 42.1 % \approx 42.1\% ≈ 42.1% .

Clinical Significance: Notice that surgical site (upper abdominal or intrathoracic incision) and surgical duration ( > 3 hours >3\text{ hours} > 3 hours ) contribute enormous weight to the score due to diaphragmatic splinting, impaired functional residual capacity ( F R C FRC FRC ), and atelectasis formation.

5. Preoperative Fasting Guidelines and Gastric POCUS

Pulmonary aspiration of gastric contents is a devastating anaesthetic complication, leading to chemical pneumonitis (Mendelson's syndrome), acute hypoxemic respiratory failure, and death. Fasting protocols minimize residual gastric volume while avoiding prolonged dehydration and ketosis.

European Preoperative Fasting Guidelines

Two European documents apply: the European Society of Anaesthesiology (ESA, now ESAIC) 2011 guideline for adults and children, and the ESAIC 2022 paediatric fasting guideline, which shortened the intervals for children. [ EUROPEAN FASTING INTERVALS FOR ELECTIVE SURGERY ]

  • ADULTS (ESA 2011)
  • Clear fluids ............ until 2 h before induction
  • Solid food .............. until 6 h before induction
  • CHILDREN (ESAIC 2022)
  • Clear fluids ............ until 1 h before induction
  • Breast milk ............. until 3 h before induction
  • Formula / non-human milk until 4 h before induction
  • Solid food .............. until 6 h before induction

Clear Fluids — 2 hours in adults, 1 hour in children: Water, pulp-free fruit juice, tea or coffee (the adult guideline accepts a small amount of milk, up to about one-fifth of the cup), and carbohydrate-rich preoperative drinks. Clear liquids leave the stomach exponentially with a half-time of roughly 15 − 20 minutes 15-20\text{ minutes} 15 − 20 minutes , so little residual volume remains at the fasting limit.

Breast Milk — 3 hours (ESAIC 2022 paediatric guideline): The older European and ASA recommendation was 4 hours.

Formula and Non-Human Milk — 4 hours in infants and children (ESAIC 2022): Cow's milk curdles in gastric acid, so in adults it is treated like food.

Solid Food — 6 hours: Applies to a light meal (e.g., toast and tea) in both adults and children.

8 Hours — Fried or Fatty Meals and Meat: This additional interval comes from the American Society of Anesthesiologists (ASA) 2017 practice guideline rather than the European guidelines; such meals empty more slowly.

Important Provisos: These guidelines apply strictly to elective patients without conditions causing delayed gastric emptying (e.g., gastroparesis, trauma, opioid administration, active labor, bowel obstruction, or acute pain).

Gastric Point-of-Care Ultrasound (POCUS)

Gastric POCUS has emerged as an objective bedside tool to evaluate gastric contents and aspiration risk when fasting status is ambiguous or delayed emptying is suspected.

Scanning Technique: A curvilinear low-frequency transducer ( 2 − 5 MHz 2-5\text{ MHz} 2 − 5 MHz ) is placed in the epigastrium in a sagittal or parasagittal plane. The gastric antrum is imaged between the left lobe of the liver anteriorly, the pancreas posteriorly, and the abdominal aorta or inferior vena cava.

Anatomical Positions: Evaluated first in the supine position , and subsequently in the right lateral decubitus (RLD) position (which shifts gravity-dependent fluid into the antrum).

Perlas Qualitative Grading System

Grade 0 (Empty Stomach): The antrum appears completely collapsed with flat, opposing anterior and posterior walls (resembling a "bull's eye" or "target"). Antrum is empty in both supine and RLD positions. Indicates negligible gastric volume ( < 0.4 mL/kg <0.4\text{ mL/kg} < 0.4 mL/kg ); extremely low aspiration risk.

Grade 1 (Low-Volume Clear Fluid): The antrum appears empty or collapsed in the supine position, but clear hypoechoic fluid is visualized when the patient turns into the right lateral decubitus (RLD) position. Correlates with physiological baseline gastric secretions ( < 1.5 mL/kg <1.5\text{ mL/kg} < 1.5 mL/kg ); considered safe for elective induction in the vast majority of patients.

Grade 2 (High-Volume Clear Fluid): Clear hypoechoic fluid is readily visible distending the gastric antrum in both supine and RLD positions . Correlates with elevated gastric volume ( > 1.5 mL/kg >1.5\text{ mL/kg} > 1.5 mL/kg ); signifies high aspiration risk. Elective surgery should be postponed, or rapid sequence induction (RSI) employed.

Solid Contents (Any Position): Presence of hyperechoic particulate material with acoustic shadowing ("frosted glass" appearance). Indicates a full stomach regardless of position; elective procedures must be delayed.

6. Perioperative Chronic Medication Management

Managing chronic pharmacotherapy requires balancing the risk of rebound physiological exacerbations against adverse anaesthetic drug interactions.

Medication Class Management Strategy Pharmacological Rationale and Clinical Nuances

β \beta β -Blockers CONTINUE without interruption Abrupt cessation precipitates severe rebound hypertension, reflex tachycardia, and myocardial ischemia. Warning: Do NOT initiate de novo high-dose β \beta β -blockers on the morning of surgery (POISE trial demonstrated increased stroke and all-cause mortality).

Statins (HMG-CoA Reductase Inhibitors) CONTINUE without interruption Pleiotropic effects: stabilizes atheromatous plaques, reduces vascular endothelial inflammation, and diminishes perioperative MACE.

ACE Inhibitors (ACEi) & ARBs Consider withholding on the day of surgery (ESC 2022, patients without heart failure) Blocking the renin-angiotensin-aldosterone axis impairs compensation for anaesthetic-induced vasodilation, increasing post-induction hypotension, which is occasionally refractory to phenylephrine and ephedrine and needs vasopressin or norepinephrine. In STOP-or-NOT (2024), stopping 48 hours beforehand and continuing produced similar major complication rates, but continuation caused more intraoperative hypotension.

Aspirin (Secondary Prevention) CONTINUE in most intermediate/high cardiac risk patients Cessation causes platelet rebound hypercoagulability and stent thrombosis. Withhold only in operations with catastrophic bleeding consequences (intracranial neurosurgery, posterior eye chamber surgery, spinal canal surgery).

P2Y12 Inhibitors STOP prior to surgery : Clopidogrel: 5 days ; Ticagrelor: 3--5 days ; Prasugrel: 7 days Irreversible inhibition of ADP P 2 Y 12 P2Y_{12} P 2 Y 12 ​ receptors on platelets. If emergency surgery is required within this window, anticipate platelet transfusion requirements.

Direct Oral Anticoagulants (DOACs) STOP based on bleeding risk and CrCl : Low bleeding risk: 24 hours ; High bleeding risk / Neuraxial: 48--72 hours Apixaban, rivaroxaban, and edoxaban (Factor Xa inhibitors); dabigatran (direct thrombin inhibitor). Dabigatran is 80 % 80\% 80% renally cleared; with CrCl \text{CrCl} CrCl 30 − 49 mL/min 30-49\text{ mL/min} 30 − 49 mL/min the ESC 2022 interval is at least 48 hours 48\text{ hours} 48 hours for low-risk and 96 hours 96\text{ hours} 96 hours for high-risk surgery.